Ginkgo Bioworks Aktie News

Ginkgo Bioworks is using a unique approach to laboratory automation. It's also spending a lot of its finite supply of money on this endeavor.

Shares of Ginkgo Bioworks have been beaten severely in response to heavy financial losses. The company's cell foundry could disrupt the biopharmaceutical manufacturing industry.

Ginkgo Bioworks reported a steep fall in revenue but lower losses earlier this month. Losses mainly shrank due to cuts in workforce and research and development; not good signs for a growth stock.

Ginkgo Bioworks has been focusing on developing its artificial intelligence capabilities to enhance its cell programming platform. The company's results, however, have been underwhelming, with sales falling by more than 50% last quarter.

Small-cap stocks have historically responded positively to interest-rate cuts. These four small-cap equities may be poised for a bull run once the Fed eventually slashes rates.

Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.

BOSTON , May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. TD Cowen's 2nd Annual Sustainability Week: Ginkgo's Senior Director of Policy and Partnerships, Ryan Morhard, will participate in the virtual Sustainable API Manuf...

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON , May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced ...